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In the last decade, our molecular and cellular 
understanding of cancer has been tremen-
dously ameliorated. It has been demonstrated 
that, in some cellular settings, microRNAs 
(miRNAs) can exert bona fide oncogenic or 
oncosuppressive functions (Croce, 2009) and 
that cancer cells often, if not always, exhibit 
an extensive metabolic rewiring (Kroemer 
and Pouyssegur, 2008); the compartment of 
cancer stem cells has been intensely studied 
(Visvader and Lindeman, 2008); the concepts 
of oncogene/non-oncogene addiction (Luo 
et al., 2009) and of immunogenic cell death 
(Zitvogel et al., 2010) have been founded; and 
novel modalities of programmed cell death 
have been characterized (Vandenabeele et al., 
2010), just to mention a few examples. These 
advances in our fundament knowledge of 
molecular and cellular cancer biology are 
rapidly being translated into ever more reli-
able diagnostic and prognostic biomarkers as 
well as into a large armamentarium of novel 
therapeutic  tools.  Personalized  anticancer 
strategies,  which  at  the  end  of  the  1990s 
held great expectations, have now turned 
into a clinically exploitable reality. Moreover, 
there is now an emerging tendency to con-
ceive tumors as micro-ecosystems that are 
composed by a heterogeneous population of 
cancer (stem) cells as well as a plethora of dis-
tinct stromal cells, including fibroblasts and 
endothelial cells, which either promote or 
limit tumor growth at the metabolic, archi-
tectonic, trophic, and immunological levels.
New  knowledge  generates  new  ques-
tions,  and  there  also  remain  several  old 
unresolved issues. For instance, do cancer 
stem cells occupy a physical niche within 
solid tumors of do they represent a func-
tional  compartment  only?  How  can  we 
exploit cancer stem cell biology to increase 
their sensitivity to therapy? How can we 
induce the immunogenic demise of tumor 
cells and hence circumvent their resistance 
to conventional anticancer regimens? What 
components of the molecular machinery 
for necroptosis might be exploited for the 
generation of novel cytotoxic agents that 
do not operate via apoptosis? How can we 
target  the  tumor-stroma  for  developing 
safe and efficient anticancer strategies? Will 
nanoparticles and other molecular targeting 
devices progress until clinical applications? 
These are only some of the great questions 
that will drive the work of us, as cellular 
and molecular oncologists, for the next few 
years. We must concentrate our efforts to 
reach an ever more precise characterization 
of the mechanisms that underlie the origin, 
survival, and therapeutic response of cancer. 
It can be anticipated that this will lead to the 
development of new, efficient approaches 
for the treatment of this dreadful disease.
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